Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1157051 | 0.86 | ADAMTS4 (0.39) | ALDH1A1LMNAGAA | |
| SCHEMBL1156706 | 0.85 | AKR1C3 (0.39) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL1580924 | 0.83 | LMNA (0.49) | ALDH1A1LMNAKMT2AMEN1HTT | |
| SCHEMBL1157066 | 0.82 | ALDH1A1 (0.47) | ALDH1A1LMNAKMT2AMEN1HTT | |
| Hydrochloric Acid SCHEMBL1156936 | 0.82 | LMNA (0.48) | ALDH1A1LMNAKMT2AMEN1HTT | |
| SCHEMBL1156390 | 0.80 | ADAMTS4 (0.39) | — | |
| SCHEMBL1157063 | 0.80 | KMT2A (0.48) | ALDH1A1LMNAKMT2AMEN1HTT | |
| SCHEMBL1156779 | 0.80 | KMT2A (0.44) | ALDH1A1LMNAKMT2AMEN1HTT | |
| SCHEMBL1156776 | 0.79 | LMNA (0.45) | ALDH1A1LMNAKMT2AMEN1HTT | |
| SCHEMBL1963934 | 0.77 | ALDH1A1 (0.36) | ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048909-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-01 | — | — | US | disclosed |
| EP-2336107-A2 | Proton pump inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20110028476-A1 | PROTON PUMP INHIBITORS | KAJINO MASAHIRO | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028476-A1 | PROTON PUMP INHIBITORS | HRH2, HRH4, CYP2C19 | ALDH1A1 2505/4885LMNA 3735/4885KMT2A 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.